References
- Rashed AH. The fast of Ramadan. Br Med J 1992;304:521-2
- Salti I, Bénard E, Detournay B, et al. Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care, 2004;27:2306?11
- Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care, 2010;33:1895-902
- Hanif MW, Valsamakis G, Dixon A, et al. Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. Diabetes Obes Metab 2008;10:755-62
- Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
- Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
- Garber AJ, Foley JE, Banerji MA. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diabetes Obes Metab 2008;10:1047-56
- Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
- Matthews DR, Dejager S, Ahrén B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain. Diabetes Obes Metab 2010;12:780-9
- Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27:318-26
- Al-Arouj M, Hassoun AA, Medlej R, et al. The effect of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract 2013;67:957-63
- Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63:1446?50
- Shaltout I, Pathan MF, Medlej R, et al. VIRTUE study: effects of vildagliptin versus sulphonylureas as monotherapy or combined with metformin in Muslim patients with type 2 diabetes fasting during Ramadan. Poster presented at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting. Vienna, Austria, 15–19 September 2014
- Al-Arouj M, Assaad-Khalil S, Buse J et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895-902
- Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011;27:1367-74
- Ibrahim MA. Managing diabetes during Ramadan. Diabetes Voice 2007;52:19-22
- Hui E, Bravis V, Hassanein M, et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:c3053
- Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-54
- Hassoun A, Pathan MF, Medlej R, et al. Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2016;9:225-31